Compare · BGLC vs ILMN
BGLC vs ILMN
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $40.46B, about 11295.5x BGLC ($3.6M).
- ILMN has been more active in the news (8 items in the past 4 weeks vs 2 for BGLC).
- ILMN has more recent analyst coverage (25 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- Illumina Inc.
- Price
- -
- -
- Market cap
- $3.6M
- $40.46B
- 1M return
- -16.44%
- -
- 1Y return
- -77.30%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest BGLC
- SEC Form 8-K filed by BioNexus Gene Lab Corp
- RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
- Chief Executive Officer Tan Lee Su-Leng was granted 338,709 shares (SEC Form 4)
- Director Yap Chee Keong was granted 32,258 shares (SEC Form 4)
- Director Bin Abdul Hamid Muhammad Azrul was granted 32,258 shares (SEC Form 4)
- Chief Financial Officer Chong Set Fui was granted 96,774 shares (SEC Form 4)
- Director Low Jook Yuen was granted 16,129 shares, increasing direct ownership by 1,279% to 17,390 units (SEC Form 4)
- SEC Form 10-Q filed by BioNexus Gene Lab Corp
- New insider Fidelion Diagnostics Pte. Ltd. claimed ownership of 392,329 shares (SEC Form 3)
- New insider Tan Lee Su-Leng claimed no ownership of stock in the company (SEC Form 3)
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)